专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20120034221A1 T-Cell Receptor Antibodies And Methods of Use Thereof 审中-公开
标题翻译： T细胞受体抗体及其使用方法
公开(公告)号：US20120034221A1
公开(公告)日：2012-02-09
申请号：US13273282
申请日：2011-10-14
申请人： Ezio Bonvini , Leslie S. Johnson , Nadine Tuaillon , Ling Huang
发明人： Ezio Bonvini , Leslie S. Johnson , Nadine Tuaillon , Ling Huang
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , C12P21/02 , C12N1/21 , C12N5/10 , C12N1/19 , A61P37/06 , A61P35/00 , A61P29/00 , A61P3/10 , A61P17/06 , A61P1/00 , A61P25/00 , C07K16/28
CPC分类号： C07K16/2809 , A61K2039/505 , C07K2317/52 , C07K2317/56 , C07K2317/71
摘要： The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the α chain of the TCR, or otherwise specifically binds the α chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies.
摘要翻译：本发明涉及特异性结合T细胞抗原受体（TCR）及其用于免疫调节的单克隆抗体或其抗原结合片段的生产和使用。在优选的实施方案中，本发明的抗体或抗原结合片段特异性结合TCR的α链的恒定区，或以其他方式特异性结合α链，而不管TCR克隆来源（即TCR的泛特异性）。本发明的抗体可用于例如用于移植维持的免疫抑制疗法和治疗自身免疫性疾病，和/或用作治疗T细胞恶性肿瘤的靶向分子。

12. 发明申请

US20090191195A1 Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof 有权
标题翻译： FcgammaRIIB特异性抗体和CD20特异性抗体的组合及其使用方法
公开(公告)号：US20090191195A1
公开(公告)日：2009-07-30
申请号：US12342305
申请日：2008-12-23
申请人： Nadine Tuaillon , Christopher Rankin
发明人： Nadine Tuaillon , Christopher Rankin
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K45/06 , A61K2039/507 , C07K16/283 , C07K16/2887 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , G01N33/54393 , G01N33/564 , G01N33/574 , G01N33/57426
摘要： The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies bind FcγRIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-FcγRIIB antibody and an anti-CD20 antibody.
摘要翻译：本发明涉及治疗，预防，治疗或改善与CD20表达相关的疾病或病症的一种或多种症状的方法，其包括以下组合的组合：（A）一种或多种特异性结合FcγRIIB，特别是人FcγRIIB的抗体，具有比所述抗体更大的亲和力结合FcγRIIA，和（B）特异性结合CD20的一种或多种抗体。这些方法包括治疗，预防，控制或改善B细胞相关疾病或病症或炎症性疾病的一种或多种症状的方法。本发明还提供了包含抗FcgammaRIIB抗体和抗CD20抗体的药物组合物。

13. 发明申请

US20070036799A1 Identification and engineering of antibodies with variant Fc regions and methods of using same 有权
标题翻译：具有变体Fc区的抗体的鉴定和工程及其使用方法
公开(公告)号：US20070036799A1
公开(公告)日：2007-02-15
申请号：US11502820
申请日：2006-08-10
申请人： Jeffrey Stavenhagen , Sergey Gorlatov , Christopher Rankin , Nadine Tuaillon
发明人： Jeffrey Stavenhagen , Sergey Gorlatov , Christopher Rankin , Nadine Tuaillon
IPC分类号： A61K39/395 , G01N33/574 , C07H21/04 , C12P21/06 , C07K14/82 , C07K16/30
CPC分类号： G01N33/574 , A61K2039/505 , C07K16/283 , C07K16/2887 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/52 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
摘要翻译：本发明涉及包括变体Fc区的分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区相对于包含野生型Fc区的可比较分子，以更大的亲和力结合FcγRIIIA和/或FcγRIIA。本发明的分子特别可用于预防，治疗或改善与疾病，病症或感染相关的一种或多种症状。本发明的分子特别可用于治疗或预防需要通过FcγAMR介导的效应细胞功能增强的功效（例如ADCC）的疾病或病症，例如癌症，感染性疾病和增强治疗功效的治疗性抗体，其作用由ADCC介导。

14. 发明申请

US20060177439A1 FcgammaRIIB-specific antibodies and methods of use thereof 审中-公开
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US20060177439A1
公开(公告)日：2006-08-10
申请号：US11305787
申请日：2005-12-15
申请人： Scott Koenig , Maria Veri , Nadine Tuaillon
发明人： Scott Koenig , Maria Veri , Nadine Tuaillon
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： A61K39/00 , A61K2039/505 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
摘要翻译：本发明涉及特异性结合FcγRIIB细胞外结构域，特别是人FcγRIIB的抗体或其片段，并阻断人FcγRIIB的Fc结合位点。本发明提供了通过施用本发明的抗体来增强免疫应答来治疗癌症和/或调节免疫复合物介导的细胞活化的方法。本发明还提供了通过施用本发明的抗原 - 抗体复合物和抗体来破坏对抗原的耐受性的方法。

15. 发明授权

US08968730B2 FcγRIIB specific antibodies and methods of use thereof 有权
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08968730B2
公开(公告)日：2015-03-03
申请号：US12167765
申请日：2008-07-03
申请人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon
发明人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon
IPC分类号： A61K39/395 , A61K39/40 , C07K16/28 , C07K16/00 , A61K39/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/54 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
摘要翻译：本发明涉及特异性结合FcγRIIB细胞外结构域，特别是人FcγRIIB的抗体或其片段，并阻断人FcγRIIB的Fc结合位点。本发明提供了通过施用本发明的抗体来增强免疫应答来治疗癌症和/或调节免疫复合物介导的细胞活化的方法。本发明还提供了通过施用本发明的抗原 - 抗体复合物和抗体来破坏对抗原的耐受性的方法。

16. 发明申请

US20140328843A1 Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof 有权
标题翻译： FcgammaRIIB特异性抗体和CD20特异性抗体的组合及其使用方法
公开(公告)号：US20140328843A1
公开(公告)日：2014-11-06
申请号：US14295579
申请日：2014-06-04
申请人： Nadine Tuaillon , Christopher Rankin
发明人： Nadine Tuaillon , Christopher Rankin
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： A61K39/39558 , A61K45/06 , A61K2039/507 , C07K16/283 , C07K16/2887 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , G01N33/54393 , G01N33/564 , G01N33/574 , G01N33/57426
摘要： The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies bind FcγRIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-FcγRIIB antibody and an anti-CD20 antibody.
摘要翻译：本发明涉及治疗，预防，治疗或改善与CD20表达相关的疾病或病症的一种或多种症状的方法，其包括以下组合的施用：（A）一种或多种特异性结合FcγRIIB，特别是人FcγRIIB的抗体，具有比所述抗体更大的亲和力结合FcγRIIA，和（B）特异性结合CD20的一种或多种抗体。这些方法包括治疗，预防，控制或改善B细胞相关疾病或病症或炎症性疾病的一种或多种症状的方法。本发明还提供了包含抗FcγRIIB抗体和抗CD20抗体的药物组合物。

17. 发明申请

US20110097323A1 Her2/neu-Specific Antibodies and Methods of Using Same 有权
标题翻译： Her2 / neu特异性抗体及其使用方法
公开(公告)号：US20110097323A1
公开(公告)日：2011-04-28
申请号：US12933885
申请日：2009-03-25
申请人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
发明人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
IPC分类号： A61K39/395 , C07K16/28 , A61P35/04
CPC分类号： C07K16/32 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及与已知的4D5抗体相比具有降低的糖基化的HER2 / neu特异性结合HER2 / neu的嵌合4D5抗体的抗体。本发明还涉及将4D5抗体及其组合物用于诊断，预后和治疗疾病如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的方法。

18. 发明申请

US20090092610A1 FcGammaRIIB Specific Antibodies and Methods of Use Thereof 有权
标题翻译： FcGammaRIIB特异性抗体及其使用方法
公开(公告)号：US20090092610A1
公开(公告)日：2009-04-09
申请号：US12167765
申请日：2008-07-03
申请人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon
发明人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon
IPC分类号： A61K39/395 , C07K16/28 , A61P35/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/54 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
摘要翻译：本发明涉及特异性结合FcγRIIB细胞外结构域，特别是人FcγRIIB的抗体或其片段，并阻断人FcγRIIB的Fc结合位点。本发明提供了通过施用本发明的抗体来增强免疫应答来治疗癌症和/或调节免疫复合物介导的细胞活化的方法。本发明还提供了通过施用本发明的抗原 - 抗体复合物和抗体来破坏对抗原的耐受性的方法。

19. 发明申请

US20090053218A1 FcGammaRIIB Specific Antibodies and Methods of Use Thereof 有权
标题翻译： FcGammaRIIB特异性抗体及其使用方法
公开(公告)号：US20090053218A1
公开(公告)日：2009-02-26
申请号：US12167760
申请日：2008-07-03
申请人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon , Ezio Bonvini
发明人： Scott Koenig , Maria Concetta Veri , Nadine Tuaillon , Ezio Bonvini
IPC分类号： A61K39/395 , A61P31/00
CPC分类号： C07K16/283 , A01K2267/0331 , A61K2039/505 , C07K16/2896 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition.
摘要翻译：本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还包括抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明还包括抗FcgammaRIIB抗体或其抗原结合片段与其它癌症治疗组合的用途。本发明提供了包含抗FcγRIIB抗体或其抗原结合片段的药物组合物，其量有效预防，治疗，治疗或改善癌症，例如B细胞恶性肿瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明还提供了通过施用本发明的抗体来增强治疗性抗体的效应子功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过用疫苗组合物施用本发明的抗体来增强疫苗组合物的功效的方法。

20. 发明申请

US20080112961A1 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same 审中-公开
标题翻译：具有变异Fc区的抗体的鉴定和工程及其使用方法
公开(公告)号：US20080112961A1
公开(公告)日：2008-05-15
申请号：US11869410
申请日：2007-10-09
申请人： Jeffrey B. Stavenhagen , Sergey Gorlatov , Christopher Rankin , Nadine Tuaillon
发明人： Jeffrey B. Stavenhagen , Sergey Gorlatov , Christopher Rankin , Nadine Tuaillon
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06 , C07K16/30
CPC分类号： C07K16/283 , A61K2039/505 , C07K16/18 , C07K16/2887 , C07K16/32 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease. The methods of the invention are also of use in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
摘要翻译：本发明涉及使用分子，特别是多肽，特别是包含变体Fc区的免疫球蛋白（例如抗体）治疗或预防癌症和其它疾病的方法，其中所述变体Fc区包含至少一个相对于野生型Fc区，相对于包含野生型Fc区的可比较分子，该变体Fc区以更高的亲和力结合FcγRIIIA和/或FcγRIIA。本发明的方法特别可用于预防，治疗或改善一种或多种与由FcγR受体介导的效应细胞功能（例如，ADCC）功效增强的疾病，病症或感染相关的症状，例如癌症，传染病。本发明的方法也可用于增强其作用由ADCC介导的治疗性抗体的治疗功效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式